Roche Pegasys (correction)
Executive Summary
Roche plans to submit analysis of markers of interferon activity in patients on Pegasys (peginterferon alfa-2a) combination therapy within six months of European approval. The company does not have an official postmarketing commitment to study individualized dosing (1"The Pink Sheet" July 22, p. 17)...